The James Cancer Hospital

COACH INTRODUCES FALL 2024 COLLECTION

Retrieved on: 
Tuesday, February 13, 2024
Collection, Empire, The James Cancer Hospital, Vevers, ID, Fifth Avenue, Stroke, Life, Character, Autumn, Carriage, Statue, Creative, Attitude, Beauty, Fashion design

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Coach debuted its Fall 2024 collection with a runway show at The James B. Duke House.

Key Points: 
  • NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Coach debuted its Fall 2024 collection with a runway show at The James B. Duke House.
  • Fall 2024 continued to build upon Coach (Re)Loved, its program for exploring circular craft that gives a second life to pre-loved Coach bags and materials, introducing denim, leather and shearling pieces crafted from second-hand materials, patchworked into new designs.
  • In leathergoods, Coach introduced its New York collection, debuting the Brooklyn bag and the Empire Carryall in the house's iconic leathers, bringing playful proportions to legacy silhouettes.
  • A curated selection of pieces from Fall 2024, including the Brooklyn bag and ready-to-wear featuring the collection's bow motif, as well as a limited series of upcrafted Coach (Re)Loved bags painted with iconic Coach and New York motifs, are available to buy now online and at Coach SoHo and Coach House on Fifth Avenue.

The NRP Group Brings Affordable Housing Community, The James on Grand Avenue, to North Austin

Retrieved on: 
Thursday, January 18, 2024
Other Construction & Property, Architecture, Residential Building & Real Estate, Construction & Property, Urban Planning, Engineering, Senior, Commissioner, Employment, Government, KeyBank, Housing, Multimedia, ESL, Interstate 35, The, Apple, Huntington Bancshares, Grand Avenue, Dell, Interstate Highway System, The James Cancer Hospital, CHR, Growth, Tourism

The NRP Group, Capital Area Housing Finance Corporation leadership and Williamson County officials gathered to celebrate the grand opening of north Austin’s new affordable housing development, The James on Grand Avenue.

Key Points: 
  • The NRP Group, Capital Area Housing Finance Corporation leadership and Williamson County officials gathered to celebrate the grand opening of north Austin’s new affordable housing development, The James on Grand Avenue.
  • The new apartment community brings a significant number of new affordable homes to North Austin and will provide residents with high-quality living options near a growing employment hub and a top-performing school district.
  • The James on Grand Avenue will be reserved for working families and individuals earning up to 60% of the area's median income.
  • “The NRP Group is excited to bring a new and much needed affordable community to families in Williamson County,” said Max Whipple, Vice President of Development at The NRP Group.

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers

Retrieved on: 
Tuesday, December 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Hackensack University Medical Center, Safety, Cytokine release syndrome, Senior, City, ASH, Aes, CRS, Haematopoietic system, Sepsis, Patient, Abstract, Thrombocytopenia, Blinatumomab, The James Cancer Hospital, Division, SCT, Acute lymphoblastic leukemia, Neutropenia, ORR, Encephalopathy, B-ALL, Infection, Survival, Death, CD20, Doctor of Philosophy, Society, Abstract (summary), OS, Confidence interval, TP53, LD, Cytopenia, Pharmaceutical industry, Nursing, Hematology, Brexucabtagene autoleucel, Lymphoma, MD

“The clinical results and real-world evidence presented at ASH clearly support the potential for long-term response and safety of Tecartus in aggressive blood cancers for which patients have limited treatment options,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.

Key Points: 
  • “The clinical results and real-world evidence presented at ASH clearly support the potential for long-term response and safety of Tecartus in aggressive blood cancers for which patients have limited treatment options,” said Frank Neumann, MD, PhD, Senior Vice President, Global Head of Clinical Development, Kite.
  • The median OS for patients with complete response (CR) (n=46) was 58.7 months.
  • Efficacy and safety outcomes for 23 patients with R/R MCL enrolled in ZUMA-18, a multicenter, open-label, expanded-access study of Tecartus, were also presented.
  • An analysis of a CIBMTR observational database of R/R MCL patients receiving Tecartus from 84 U.S. centers was presented.

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Retrieved on: 
Friday, December 8, 2023
FDA, Health, Stem Cells, Genetics, Pharmaceutical, Biotechnology, Einstein Medical Center Philadelphia, Food, Transplant, CRISPR Therapeutics, Therapy, Sickle cell disease, University of Chicago, Disease, Patient, Section, CRSP, Vertex Pharmaceuticals, The James Cancer Hospital, CRISPR, Committee, Volatile organic compound, Hospital, SCD, Haematopoietic system, Boston Medical Center, Pharmaceutical industry, Nursing, Vertex, Boston

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
  • “CASGEVY’s approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S. As importantly, CASGEVY is a first-in-class treatment that offers the potential of a one-time transformative therapy for eligible patients with sickle cell disease,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
  • So, this U.S. approval of the first-ever medicine using CRISPR gene editing is breathtaking, and a truly humbling moment for me personally and for the whole organization,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics.
  • The following ATCs are already activated:
    Boston Medical Center in Boston, Mass.

Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

Retrieved on: 
Monday, August 28, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ohio State University, Obstetrics, Catholic higher education, Survival, Glomus tumor, Clinical trial, Paclitaxel, Gynecologic Oncology (journal), Doctor of Philosophy, MD, Patient, Division, Catholic University of Leuven (1834–1968), Gynaecology, Ovarian cancer, The James Cancer Hospital, Medical imaging, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis.
  • Consistent with previously reported studies, TTFields therapy was well-tolerated with no added systemic toxicities.
  • An analysis of exploratory subgroups suggests a potential survival benefit in patients who received only one prior line of therapy.
  • This signal could merit further exploration given the unmet need for the ~20% of ovarian cancer patients who have a limited response to frontline platinum-based treatment.

The James Hotel NoMad Partners with FÜZI Pets to Bring Luxe Accommodations to Their Furry Guests

Retrieved on: 
Monday, August 28, 2023
James New York - NoMad, Partnership, Pet, Overalls, James, Multimedia, Dog, System, Rest, The James Cancer Hospital, Hotel, Telescopic sight, Pet industry

NEW YORK, Aug. 28, 2023 /PRNewswire-PRWeb/ -- FÜZI Pets, a leading innovator in pet furniture products, is thrilled to announce its latest partnership with The James Hotel NoMad, an iconic luxury hotel known for its curated guest experiences. This collaboration aims to provide an unparalleled level of comfort and style for the furry companions of hotel guests through the introduction of FÜZI Pet's distinctive elevated pet beds.

Key Points: 
  • New York City hotel, The James NoMad, brings modern luxe FÜZI pet beds to their pet-friendly hotel rooms.
  • NEW YORK, Aug. 28, 2023 /PRNewswire-PRWeb/ -- FÜZI Pets, a leading innovator in pet furniture products, is thrilled to announce its latest partnership with The James Hotel NoMad, an iconic luxury hotel known for its curated guest experiences.
  • This collaboration aims to provide an unparalleled level of comfort and style for the furry companions of hotel guests through the introduction of FÜZI Pet's distinctive elevated pet beds.
  • "I'd never seen a dog bed quite like FÜZI Pet's and its adaptive use, sizing and overall chic aesthetic perfectly aligned with what The James needed."

Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

Retrieved on: 
Sunday, June 4, 2023
Roswell Park Comprehensive Cancer Center, American Society of Clinical Oncology, The James Cancer Hospital, Doctor of Philosophy, Oncogene, Incidence, DO, Metabolism, Patient, The Cancer Genome Atlas, Risk, Informatics, Colorectal cancer, Body mass index, H. Lee Moffitt Cancer Center & Research Institute, TCGA, PSA, Prostate cancer, MYC, University, National Cancer Institute, AYA, Research, MS, Cancer, Diagnosis, Growth, BMI, Smoking, PD-L1, Metastasis, Behavior, NRAS, University of Oklahoma Health Sciences Center, Lipid, Cell, Dicarboxylic acid, Ohio State University, CRC, Health informatics, ASCO, Kynurenine, CDT, Gene, Society, Pharmaceutical industry, Birth control, Medical imaging, Upstate New York, MD, Roswell Park

That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.

Key Points: 
  • That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.
  • The team hopes the results of their study will help future studies zero in on new ways of treating colorectal cancer in younger patients.
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

Renowned Prostate Cancer Robotic Surgeon and Urologist Dr. John K. Burgers Joins Florida Urology Center, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, January 24, 2023
General Health, Surgery, Medical Devices, Health, Oncology, Internship, Johns Hopkins School of Medicine, Patient, Prostate cancer, Research, Medical school, Environment, The James Cancer Hospital, MD, Medical device

Florida Urology Center is an affiliate of U.S. Urology Partners , one of the nation’s leading providers of urological services.

Key Points: 
  • Florida Urology Center is an affiliate of U.S. Urology Partners , one of the nation’s leading providers of urological services.
  • An internationally recognized urologist and surgeon, Dr. Burgers has been practicing urology for 30 years and has more than 18 years of robotic surgery experience.
  • Dr. Greg A. Parr of Florida Urology Center stated, “We are honored to welcome Dr. John Burgers to our care team at Florida Urology Center .
  • In addition to his background in general urology, we are excited about Dr. Burgers’ expertise in leading edge cancer care and robotic surgery for prostate cancer patients.

Daniel M. Prevedello, MD, MBA, FACS, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, February 14, 2023
MBA, University, Crystal skull, Neurosurgery, Nose, Virgin Islands, Brain, Spinal cord, Nervous system, EEA, Spine, Music, Executive, Mentorship, Stroke, Continental, Diagnosis, Patient, Disorder, Head, The James Cancer Hospital, Paranasal sinuses, OH, Infection, Tetraplegia, To Brazil!, American Association of Neurological Surgeons, Skull, CNS, Sociedade Brasileira para o Progresso da Ciência, Family, Congress, World government, Congress of Neurological Surgeons, FACS, American College, Neoplasm, Rehabilitation, The Society of Neurological Surgeons, Sympathetic nervous system, Ohio State University Wexner Medical Center, Surgeon, Ohio State University, SBN, Dentistry, Veterinary medicine, MD

COLUMBUS, Ohio, Feb. 14, 2023 /PRNewswire/ -- Daniel M. Prevedello, MD, MBA, FACS, is being recognized by Continental Who's Who as a Top Pinnacle Professional for his contributions to the medical field.

Key Points: 
  • COLUMBUS, Ohio, Feb. 14, 2023 /PRNewswire/ -- Daniel M. Prevedello, MD, MBA, FACS, is being recognized by Continental Who's Who as a Top Pinnacle Professional for his contributions to the medical field.
  • According to Dr. Prevedello, he is a well-known neurosurgeon specializing in skull base pathologies and brain tumors.
  • Neurosurgeons are doctors who diagnose and treat problems with the nervous system, often by performing surgery on the brain or spine.
  • Dr. Prevedello would like to thank his mentors Joao Candido Araugo, MD; Edward Laws, MD; and Amin Kassam, MD.

Haute Residence and Dante DiSabato Continue Their Real Estate Partnership Into Sixth Year

Retrieved on: 
Thursday, December 15, 2022
Port Royal, National Board of Boiler and Pressure Vessel Inspectors, Shelter, Woman, Jim Jordan (American politician), Partnership, Sale, Residence, News, The James Cancer Hospital, Domestic violence, Ohio State University, Real estate

NAPLES, Fla., Dec. 15, 2022 /PRNewswire-PRWeb/ -- A concierge broker in the truest sense of the term, Dante DiSabato works tirelessly to ensure his client's satisfaction, bringing a discipline and competitive spirit to real estate that's perfectly in tune with getting the best for his customers.

Key Points: 
  • Haute Residence and acclaimed real estate agent, Dante DiSabato, take their partnership into its Sixth year.
  • As a Haute Residence member, Dante DiSabato exclusively represents the high-end real estate market in Naples, Florida.
  • Designed as a partnership-driven luxury real estate portal, Haute Residence connects its affluent readers with top real estate professionals, while offering the latest in real estate news, showcasing the world's most extraordinary residences on the market, and sharing expert advice from its knowledgeable and experienced real estate partners.
  • HauteResidence.com has grown to be the number-one news source for million-dollar listings, high-end residential developments, celebrity real estate, and more.